Clinical Management Of Hepatitis C In Patients With And Without HIV Coinfection
Andrew Talal, MD, MPH
Associate Professor of Medicine
Associate Medical Director, Center for the Study of Hepatitis C
Weill Cornell Medical College, New York, NY
COPYRIGHT: Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2011. All rights reserved.
At the completion of this educational session, participants should be able to:
- Understand the current approach to the diagnosis and staging of hepatitis C virus (HCV) infection.
- Know how HIV/HCV coinfection affects HCV pathogenesis.
- Appreciate treatment outcomes and side effect management to pegylated interferon and ribavirin in both
HCV monoinfected and HIV/HCV coinfected individuals.
Andrew Talal is Associate Professor of Medicine and Associate Medical Director at the Center for the Study of Hepatitis C at the Weill Cornell Medical College. Following his
research fellowship in Gastrointestinal Epidemiology at the University of North Carolina at Chapel Hill, Dr Talal became a Rockefeller University Clinical Scholar in the laboratory of Dr. David Ho where he investigated the pathogenesis of HIV in the gut associated lymphoid tissue. In February 2000, Dr Talal joined the faculty at Weill Cornell where he founded the Viral Hepatitis Clinic, the Center’s Translational Research Laboratory. His research interests include investigation of chemokines as mediators of fibrogenesis and noninvasive biomarkers of hepatic fibrosis. He also has been interested in HCV management in disenfranchised populations including HIV/HCV coinfected and those on opiate agonist therapy.
You must be logged in to post a comment. Login | Register
